PL3330267T3 - Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształu - Google Patents
Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształuInfo
- Publication number
- PL3330267T3 PL3330267T3 PL16830581T PL16830581T PL3330267T3 PL 3330267 T3 PL3330267 T3 PL 3330267T3 PL 16830581 T PL16830581 T PL 16830581T PL 16830581 T PL16830581 T PL 16830581T PL 3330267 T3 PL3330267 T3 PL 3330267T3
- Authority
- PL
- Poland
- Prior art keywords
- crystal
- salt
- quinazoline derivative
- producing
- quinazoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015149259 | 2015-07-29 | ||
| JP2015219635 | 2015-11-09 | ||
| PCT/JP2016/072129 WO2017018476A1 (ja) | 2015-07-29 | 2016-07-28 | キナゾリン誘導体の塩またはその結晶およびそれらの製造方法 |
| EP16830581.1A EP3330267B1 (en) | 2015-07-29 | 2016-07-28 | Salt of quinazoline derivative or crystal thereof, and method for producing salt of quinazoline derivative or crystal thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3330267T3 true PL3330267T3 (pl) | 2022-04-04 |
Family
ID=57885722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16830581T PL3330267T3 (pl) | 2015-07-29 | 2016-07-28 | Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształu |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10329285B2 (pl) |
| EP (1) | EP3330267B1 (pl) |
| JP (1) | JP6334065B2 (pl) |
| DK (1) | DK3330267T3 (pl) |
| ES (1) | ES2908349T3 (pl) |
| PL (1) | PL3330267T3 (pl) |
| TW (1) | TWI705962B (pl) |
| WO (1) | WO2017018476A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018139626A1 (ja) * | 2017-01-30 | 2018-08-02 | 塩野義製薬株式会社 | キナゾリン誘導体を含有する固形製剤 |
| JP2019208422A (ja) * | 2018-06-04 | 2019-12-12 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | ヒアルロニダーゼを含む新規な組換えエキソソーム及びその用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2413134C (en) | 2000-06-30 | 2010-05-11 | Glaxo Group Limited | Quinazoline ditosylate salt compounds |
| EP1854798A3 (en) * | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| AU2006216266C1 (en) | 2005-02-23 | 2010-08-26 | Shionogi & Co., Ltd. | Quinazoline derivative having tyrosine kinase inhibitory activity |
| WO2009079547A1 (en) | 2007-12-18 | 2009-06-25 | Smithkline Beecham (Cork) Limited | Quinazoline anhydrate forms |
| WO2009079541A1 (en) | 2007-12-18 | 2009-06-25 | Smithkline Beecham (Cork) Limited | Quinazoline ditosylate anhydrate forms |
| TWI466872B (zh) | 2008-12-25 | 2015-01-01 | Shionogi & Co | 喹唑啉衍生物之製造方法 |
-
2016
- 2016-07-28 JP JP2017530920A patent/JP6334065B2/ja active Active
- 2016-07-28 EP EP16830581.1A patent/EP3330267B1/en active Active
- 2016-07-28 ES ES16830581T patent/ES2908349T3/es active Active
- 2016-07-28 US US15/748,283 patent/US10329285B2/en active Active
- 2016-07-28 WO PCT/JP2016/072129 patent/WO2017018476A1/ja not_active Ceased
- 2016-07-28 DK DK16830581.1T patent/DK3330267T3/da active
- 2016-07-28 PL PL16830581T patent/PL3330267T3/pl unknown
- 2016-07-29 TW TW105124192A patent/TWI705962B/zh active
-
2019
- 2019-05-02 US US16/401,342 patent/US10513513B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3330267B1 (en) | 2022-01-05 |
| EP3330267A4 (en) | 2018-12-26 |
| TW201718530A (zh) | 2017-06-01 |
| ES2908349T3 (es) | 2022-04-28 |
| US20190256506A1 (en) | 2019-08-22 |
| WO2017018476A1 (ja) | 2017-02-02 |
| US10513513B2 (en) | 2019-12-24 |
| TWI705962B (zh) | 2020-10-01 |
| US20180215744A1 (en) | 2018-08-02 |
| JPWO2017018476A1 (ja) | 2018-05-17 |
| JP6334065B2 (ja) | 2018-05-30 |
| EP3330267A1 (en) | 2018-06-06 |
| US10329285B2 (en) | 2019-06-25 |
| DK3330267T3 (da) | 2022-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289910A (en) | A method for preparing allulose crystals | |
| IL259708B (en) | Method and package for recovery of salt | |
| SG10202007411RA (en) | Growing system and method | |
| EP3287444A4 (en) | New crystal form of lenvatinib methanesulfonate salt and preparation method thereof | |
| PT3470400T (pt) | Formas cristalinas de ozanimod e cloridrato de ozanimod, e processos para a preparação das mesmas | |
| SG11201707899SA (en) | Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same | |
| EP3272746A4 (en) | Salts of quinazoline derivative and method for preparing same | |
| PL3157889T3 (pl) | Kompozycja mocznikowa i sposób jej wytwarzania | |
| PL3309138T3 (pl) | Sposób koprodukcji 2,3,3,3-tetrafluoropropylenu i 1,3,3,3-tetrafluoropropylenu | |
| GB201415317D0 (en) | Process for producing fluorocytosine and fluorocytosine derivatives | |
| PT3309149T (pt) | Cristal de 6-bromo-3-hidroxi-2-pirazinocarboxamida e processo para a sua produção | |
| EP3369548A4 (en) | Case and method for producing case | |
| EP3330267A4 (en) | Salt of quinazoline derivative or crystal thereof, and method for producing salt of quinazoline derivative or crystal thereof | |
| EP3272751A4 (en) | Crystal form of ipi-145 and preparation method thereof | |
| EP3505516A4 (en) | QUINAZOLINE DERIVATIVE SALT CRYSTAL | |
| EP3263572A4 (en) | Method for producing kakeromycin and derivatives thereof | |
| IL254597A0 (en) | Crystalline form of ahu377, method for its preparation and use | |
| EP3269710A4 (en) | Nintedanib diethanesulfonate salt crystal and preparation method and use thereof | |
| HUE053626T2 (hu) | Eljárás benzopirán származék tisztítására, ennek kristályos formája, és eljárás kristályforma elkészítésére | |
| SG11201706066RA (en) | Method of producing substance | |
| PT3305790T (pt) | Método para preparação de um derivado de imidazol e seu intermediário e forma cristalina | |
| ZA201901120B (en) | Crystal and salt of nitroimidazole, and manufacturing method thereof | |
| EP3339484B8 (en) | Method for producing langatate single crystal and langatate single crystal | |
| SG11201708692WA (en) | Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof | |
| SG11201706164WA (en) | Phosphorous acid compound, method for producing said compound, and use of said compound |